Johnson & Johnson is banking on its newly launched psoriasis medication, Icotyde, to significantly boost its revenue. Approved by the FDA in mid-March for moderate to severe plaque psoriasis, Icotyde is notable for being the first oral treatment that targets the IL-23 receptor, similar to existing injectable therapies like J&J's Tremfya.
CEO Joaquin Duato expressed optimism about Icotyde's potential, suggesting it could become one of the company's largest products, especially as sales of its previous blockbuster, Stelara, decline due to the introduction of biosimilars. Stelara's revenue peaked at nearly $11 billion in 2023 but is projected to drop to $2.36 billion this year.
In contrast, Tremfya's sales are expected to rise from $3.15 billion in 2023 to an estimated $7.13 billion by 2026. Although Icotyde has received a positive initial response, with around 1,500 prescriptions written within its first month, analysts remain cautious.
Bank of America analyst Jason Gerberry noted that the convenience of a daily pill may not be enough to compete with established biologics that require less frequent administration. Comparisons were drawn to Bristol Myers Squibb's Sotyktu, which struggled to gain traction in the market.
Leerink analyst David Risinger emphasized the importance of securing insurance coverage for Icotyde, predicting its sales could reach $10.5 billion by 2032, significantly higher than the Wall Street consensus of $7.4 billion.
The success of Icotyde will depend on its approval for additional conditions like Crohn's disease and ulcerative colitis, which have historically driven sales for J&J's other products. Despite some skepticism, J&J's stock has performed well, gaining 9.55% year-to-date, outperforming the S&P 500's 8.2% increase.
The company aims for double-digit revenue growth by the end of the decade, supported by its strong pharmaceutical division. Overall, Icotyde's launch is a critical step for J&J as it seeks to maintain its leadership in the immunology market and offset declining revenues from older drugs